Copyright
©The Author(s) 2021.
World J Gastrointest Endosc. Feb 16, 2021; 13(2): 56-71
Published online Feb 16, 2021. doi: 10.4253/wjge.v13.i2.56
Published online Feb 16, 2021. doi: 10.4253/wjge.v13.i2.56
Table 1 Demographic and clinical data of the study population, n (%)
Patients | n = 35 |
Age (yr) | 66.7 ± 14.5 |
Male gender | 17 (48.6) |
ASA I-II | 25 (71.4) |
AAS | 5 (14.3) |
Smoking | 12 (34.3) |
History of acute pancreatitis | 3 (8.6) |
History of extrapancreatic neoplasia | 10 (28.6) |
Family history of pancreatic cancer | 3 (8.6) |
Symptoms | 10 (28.6) |
Table 2 Morphological characteristics
Radiological imaging tests | n (%) |
Malignant | 7 (19.4) |
Non-malignant | 29 (80.6) |
Worrisome features on EUS | 18 (50) |
EUS diagnosis | |
Malignant | 4 (11.1) |
BD-IPMN | 9 (25) |
MD-IPMN | 14 (38.9) |
MCN | 5 (13.9) |
SCN | 4 (11.1) |
Location | |
Head | 21 (58.3) |
Body | 15 (41.7) |
Tail | 0 |
Multifocal | 8 (22.9) |
Size (mm) | 27 ± 15.5 |
Size MPD > 3 mm | 11 (30.6) |
Mural nodule | 8 (22.2) |
Contrast enhancement pattern | |
Hypo/iso-enhanced walls | 18 (54.5) |
Hyperenhanced walls | 12 (36.4) |
Mixed enhancement pattern | 3 (9.1) |
Table 3 Cyst fluid analysis
Biochemical | n (%) |
CEA (n = 29) | |
< 192 ng/mL | 14 (48.3) |
≥ 192 ng/mL | 15 (51.7) |
Glucose (n = 16) | |
< 50 mg/dL | 10 (62.5) |
≥ 50 mg/dL | 6 (37.5) |
Cytological | |
Papanicolau classification (n = 36) | |
II | 13 (36.1) |
IV | 22 (61.1) |
VI | 1 (2.8) |
Mucin staining (n = 36) | |
Positive | 22 (61.1) |
Negative | 14 (38.9) |
Molecular | |
Possible | 25 (69.4) |
Not possible | 11 (30.6) |
Table 4 Molecular analysis
Non-mucinous | Mucinous | ||||||||||||||||||||||
PCN5 | PCN15 | PCN18 | PCN20 | PCN33 | PCN0 | PCN1 | PCN2 | PCN3 | PCN4 | PCN7 | PCN11 | PCN13 | PCN14 | PCN16 | PCN17 | PCN19 | PCN21 | PCN24 | PCN25 | PCN29 | PCN30 | PCN34 | |
KRAS | M | M | N | N | M | M | N | N | N | N | M | N | N | N | N | M | N | N | N | M | M | N | N |
GNAS | M | M | N | N | M | N | N | N | N | N | N | N | M | N | N | M | M | N | M | M | M | M | M |
VHL | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
P53 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
PIK3R1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | N | M | M | M |
EGFR | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
ALK | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
NOTCH1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
GNA11 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
CDKN2A | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
APC | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
FGFR2 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
IDH1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | N | M | M | M | M | M | M |
PIK3CA | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
KIT | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
MET | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
FGFR1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
ROS1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
GNAQ | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
PDGFRA | M | M | M | M | M | M | M | M | N | M | M | M | M | M | M | M | M | M | M | M | N | M | N |
FGFR3 | N | M | M | M | M | M | M | M | M | M | M | M | M | N | M | M | M | M | M | M | M | M | M |
RNF43 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
RET | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | N |
ERBB2 | M | M | M | M | M | M | M | M | N | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
DDR2 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
BRAF | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | N | M |
ESR1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
FGFBR2 | M | M | M | M | M | M | N | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
FBXW7 | M | M | N | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
FOXL2 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
MAP2K1 | M | M | M | M | M | M | M | N | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
AKT1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
CTNNB1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
SMAD4 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
PTEN | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
NRAS | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
IDH2 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
HRAS | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
CDH1 | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M | M |
- Citation: Herranz Pérez R, de la Morena López F, Majano Rodríguez PL, Molina Jiménez F, Vega Piris L, Santander Vaquero C. Molecular analysis of pancreatic cystic neoplasm in routine clinical practice. World J Gastrointest Endosc 2021; 13(2): 56-71
- URL: https://www.wjgnet.com/1948-5190/full/v13/i2/56.htm
- DOI: https://dx.doi.org/10.4253/wjge.v13.i2.56